COMMUNIQUÉS West-GlobeNewswire

MacroGenics Appoints Eric Risser as President and Chief Executive Officer
13/08/2025
ROCKVILLE, MD, Aug. 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company developing innovative antibody-based therapeutics for the treatment of cancer, today [...]
Hyperion DeFi Provides Corporate Update and Reports Second Quarter 2025 Financial Results
13/08/2025
Successfully establishes cryptocurrency treasury reserve focused on the HYPE token and becomes the first publicly listed U.S. company to implement DeFi strategies on Hyperliquid blockchain Accumulates more than 1.5 [...]
Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
13/08/2025
Tevogen.AI to explore external market opportunities as a potential revenue source. Beta version to incorporate oncology targets, enhancing the accuracy and diversity of the PredicTcell model and potentially accelerating [...]
Building Muscle After 50: Why CrazyBulk Muscle Growth & Strength Supplements for Over 50's are Best Sellers in 2025
13/08/2025
New York City, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- In 2025, CrazyBulk is redefining building muscle after 50 by boosting healthy testosterone levels, improving mTOR responsiveness, and enhancing recovery - so men 50+ [...]
Milestone Scientific Schedules Second Quarter 2025 Financial Results and Business Update Conference Call
13/08/2025
ROSELAND, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that [...]
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 juillet 2025
13/08/2025
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 juillet 2025 DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE En application de l' [...]
Erdem Hospital Performs First-of-Its-Kind Spinal Revision Surgery
13/08/2025
Groundbreaking procedure restores mobility to Italian patient after years of paralysis Photo: Erdem Hospital via FL Communications ISTANBUL, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Erdem Hospital has announced the successful [...]
Muscular Endurance: Bodybuilders Choose CrazyBulk Bodybuilding Supplements For Peak Performance & Strength Building
13/08/2025
Discover how CrazyBulk’s legal bodybuilding supplements can enhance muscular endurance, boost strength, and speed up recovery. Learn optimal stacks, training integration tips, and where to buy authentic CrazyBulk [...]
Natural Weight Loss Supplements: How PhenQ Became the Leading Alternative to Anti-Obesity Injections in 2025
13/08/2025
London, UK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- PhenQ leads 2025 with a multi-action, science-informed approach to weight loss - no needles, no prescriptions, just clean, sustainable natural weight management that fits [...]
Positron Corporation Secures Multi-Unit Sale of PET-CT Scanners to Leading Cardiology Group
13/08/2025
Niagara Falls, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leader in molecular imaging technology and services, today announced the sale of four (4) PET-CT 64- [...]
Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT - Advancing Breakthrough Therapy for Chronic Lower Back Pain
13/08/2025
PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) , a clinical-stage biotechnology company focused on regenerative and immune cellular therapies, today announced that [...]
MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy
13/08/2025
Cancer-fighting immunosuppressive agents shown to disrupt telomeres and suspend growth of cancer cells CHICAGO , Aug. 13, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), [...]
Dogwood Therapeutics Reports Second Quarter 2025 Financial Results
13/08/2025
- Enrollment to-date of 52 patients in the ongoing Halneuron ® Phase 2b Trial - - Halneuron ® Chemotherapy-Induced Neuropathic Pain (“CINP”) Phase 2b study interim data readout remains on track for Q4 2025 - - Low [...]
Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update
13/08/2025
– Initiated Phase 2 Seabreeze STAT asthma and COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations – – Presented positive data at ATS 2025 and EAACI 2025 supporting the potential of [...]
ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones
13/08/2025
KEY HIGHLIGHTS First clinical site for Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease (DKD) was activated June 2025; patient screening is underway, with interim [...]
24/7 Market News: LIXTE Biotechnology Holdings Embraces Cryptocurrency in Corporate Treasury Strategy
13/08/2025
DENVER, Aug. 13, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com , a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, reports that LIXTE Biotechnology Holdings [...]
MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers
13/08/2025
MediWound Announces New EscharEx ® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers Post hoc analysis published in Advances in Wound Care, provides clinical [...]
Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor
13/08/2025
Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept demonstrated a favorable safety profile Vor evaluating timing of global Phase 3 clinical study in [...]
Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection
13/08/2025
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class [...]

Pages